KYMERA THERAPEUTICS, INC. Payments to Acquire Marketable Securities
KYMERA THERAPEUTICS, INC. (KYMR) reported Payments to Acquire Marketable Securities of $1.01 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-02-26
- KYMERA THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2020-12-31 was $68.44M.
- KYMERA THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2019-12-31 was -$62.16M.
- KYMERA THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2025 was $1.01B, a 11.81% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2024 was $901.23M, a 376.46% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2023 was $189.15M, a 57.59% decline from fiscal 2022.
- KYMERA THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2022 was $445.97M, a 2.29% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|
| 2025-12-31 | $1.01B 10-K · filed 2026-02-26 | ||
| 2024-12-31 | $901.23M 10-K · filed 2026-02-26 | ||
| 2023-12-31 | $189.15M 10-K · filed 2026-02-26 | ||
| 2022-12-31 | $445.97M 10-K · filed 2025-02-27 | ||
| 2021-12-31 | $456.40M 10-K · filed 2024-02-22 | ||
| 2020-12-31 | $68.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $529.38M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $460.94M 10-Q · filed 2020-11-05 | ||
| 2019-12-31 | -$62.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $15.95M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $78.11M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |